MedTrace Logo

Treatment of Covid-19 With a Herbal Compound, Xagrotin

NCT05017493 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 661

Last updated 2021-12-02

Study results available
· View outcomes & findings →

Summary

This is an interventional, multi-center, randomized study. Adults with confirmed covid-19 disease not more than 10 days before enrollment date were recruited (n=361). Patients in same condition who had treated with standard of care were randomly assigned to the control group (n=178). The investigators analyzed the effect of a herbal compound, Xagrotin, and also investigated impact of different characteristics for instance gender, age, duration of disease, smoking habits and concomitant diseases on the outcome.

Conditions

  • Covid19

Interventions

COMBINATION_PRODUCT

Xagrotin

A group of patients were treated with Xagrotin with or without standard of care, the control group received stadard of care

Sponsors & Collaborators

  • Directorate of Health of Sulaimani, Iraq

    collaborator OTHER

  • Biomad AS

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-01
Primary Completion
2020-12-07
Completion
2021-02-08

Countries

  • Iraq

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05017493 on ClinicalTrials.gov